title: Improving Survival of Pancreatic Cancer. What Have We Learnt?
abstract: Pancreatic adenocarcinoma still ranks high among cancer-related deaths worldwide. In spite of substantial strides in preoperative staging, surgery, perioperative care, and adjuvant treatment, the survival still remains dismal. A number of patient-, disease-, and surgeon-related factors play a role in deciding the eventual outcome of the patient. The aim of this commentary is to review the current knowledge of various factors and the recent advances that impact the survival of patients with pancreatic adenocarcinoma. A search of scientific literature using Embase and MEDLINE, for the years 1985-2015, was carried out for search terms "pancreatic cancer" and "survival." Further search was based on the various specific prognostic factors that contribute towards survival of patients with pancreatic cancer found in the literature. Most of the studies used for this review include those that deal with pancreatic head cancers, some include patients with pancreatic cancers in all locations while very few included patients with tumors of body and tail only. In spite of significant developments in pre- and perioperative management, increased rates of margin-negative resections, and use of adjuvant treatment, the survival rates of pancreatic cancer patients remains poor. A paradigm shift with more effective adjuvant regimen and genetic interventions may help change the outcomes of patients with pancreatic cancer.
authors.affiliation: Division of GI Surgery, GI Oncology, Minimal Access and Bariatric Surgery, Medanta, The Medicity Hospital, Gurgaon, 122001 India.
authors.forename: Tanveer
authors.initials: T
authors.lastname: Singh
authors.affiliation: Division of GI Surgery, GI Oncology, Minimal Access and Bariatric Surgery, Medanta, The Medicity Hospital, Gurgaon, 122001 India.
authors.forename: Adarsh
authors.initials: A
authors.lastname: Chaudhary
keywords: Borderline resectable; Complications; Neoadjuvant therapy; Pancreatic cancer; Survival